Physician profile
Mark T Lin
NPI 1366594749
$2,935.01
in general payments reported to CMS, 2019-2025
30 companies · $1,084 in 2025
The $1,084 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $61.80 · 2021: $13.21 · 2022: $24.11 · 2023: $798 · 2024: $487 · 2025: $1,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,356 · Education: $12.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,355.91 |
| Education | $12.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $756.84 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $486.04 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $223.55 | 2019-2025 | |
| Janssen Biotech, INC. | $214.93 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Medtronic, INC. | $174.41 | 2023 | Signia |
| Phathom Pharmaceuticals, INC. | $134.40 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $112.73 | 2019-2025 | Ocaliva |
| Genzyme Corporation | $103.51 | 2022-2025 | |
| Ucb, INC. | $69.72 | 2019 | |
| Ardelyx, INC. | $54.08 | 2024-2025 | Ibsrela |
| Braintree Laboratories, INC. | $52.08 | 2021-2025 | Suflave, Sutab |
| Amgen INC. | $47.51 | 2025 | Uplizna, Tavneos |
| Regeneron Healthcare Solutions, INC. | $38.23 | 2024-2025 | Dupixent |
| Allergan, INC. | $36.12 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $35.61 | 2023-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $28.16 | 2025 | Zenpep |
| Sandoz INC. | $27.12 | 2023 | Hyrimoz |
| Ipsen Biopharmaceuticals, INC | $24.18 | 2025 | Iqirvo |
| Mylan Institutional INC. | $22.96 | 2023 | Hulio |
| Ironwood Pharmaceuticals, INC | $21.54 | 2019 | |
| Organon LLC | $20.30 | 2024 | |
| Shire North American Group INC | $20.10 | 2019 | |
| Qol Medical, LLC | $17.91 | 2019 | |
| Olympus America INC. | $17.43 | 2024 | Gastrointestinal Videoscope |
| Lilly USA, LLC | $16.95 | 2025 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.56 | 2023 | Cyltezo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.89 | 2025 | Xifaxan |
| Ultragenyx Pharmaceutical INC. | $13.86 | 2025 | Dojolvi |
| Echosens North America, INC. | $11.29 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.